Biolidics' Covid-19 rapid test kit allowed to be marketed, sold in US
SINGAPORE-BASED cancer diagnostics company Biolidics can now distribute, market and sell its Covid-19 rapid test kits in the US, it said in a bourse filing on Monday.
The Catalist-listed firm completed its listing with the US Food and Drug Administration (FDA) on April 17.
Its test kits are allowed for use by clinical laboratories or healthcare workers for point-of-care testing, but not for home testing.
In its filing, Biolidics said that its test kits are solely used for identifying antibodies to SARS-CoV-2, which is the virus that causes Covid-19.
Its test reports must also state that the tests have not been reviewed by the FDA. A negative result from testing does not rule out a SARS-CoV-2 infection, while a positive result could be due to past or present infections with non-SARS-CoV-2 strains, such as coronavirus HKU1, NL63, OC43, or 229E.
The company's test kits are already allowed for sale in the European Union. It has also received approval for the test kits from Singapore's Health Sciences Authority and the Food and Drug Administration of the Philippines.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Biolidics shares were flat at 31.5 Singapore cents at Friday's close.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Telegram messaging service to allow Tether stablecoin payments
Hong Kong regulator to probe PwC auditing role over Evergrande
US: S&P, Dow open flat as Middle East jitters ease, Netflix weighs on Nasdaq
DBS puts 46 retail units, HDB shops on market for S$210 million
China to facilitate Hong Kong IPOs and expand Stock Connect
Global equity funds see surge in outflows as rate cut hopes fade